Converting from Oral Risperidone to Risperdal Consta (LAI)
Start Risperdal Consta at 25 mg IM every 2 weeks for patients on oral risperidone ≤3 mg/day, 37.5 mg for those on >3-5 mg/day, and 50 mg for those on >5 mg/day, while continuing oral risperidone (or another oral antipsychotic) for 3 weeks after the first injection to maintain therapeutic levels during the delayed release phase. 1, 2
Dose Conversion Guidelines
The FDA-approved conversion strategy requires careful attention to the delayed-release pharmacokinetics of the LAI formulation:
Equivalent Dose Matching
Use the following conversion ratios based on current oral risperidone dose: 2
- ≤3 mg/day oral → 25 mg LAI every 2 weeks
- >3 to 5 mg/day oral → 37.5 mg LAI every 2 weeks
- >5 mg/day oral → 50 mg LAI every 2 weeks
These ratios are based on a 48-week pharmacokinetic study that demonstrated patients receiving lower equivalent doses (using the original FDA conversion of ≤4 mg oral → 25 mg LAI) showed increased relapse tendency and decreased serum metabolite concentrations. 2 The maximum dose should not exceed 50 mg every 2 weeks. 1
Critical Oral Overlap Period
Continue oral risperidone (or another oral antipsychotic) for exactly 3 weeks after the first LAI injection, then discontinue. 1 This overlap is mandatory because:
- The LAI formulation has a delayed main release phase that does not provide therapeutic plasma concentrations immediately 1
- Clinical trials used specific oral doses during overlap: 2 mg oral for 25 mg LAI group, 4 mg oral for 50 mg LAI group, and 6 mg oral for 75 mg LAI group 1
- Without this overlap, patients risk symptom exacerbation during the 3-week lag period
Pre-Conversion Requirements
For patients never previously exposed to oral risperidone, establish tolerability with oral risperidone before initiating LAI. 1 This test dose period prevents committing patients to a 2-week depot formulation if they experience intolerable side effects.
Dose Adjustment Timeline
Do not increase the LAI dose more frequently than every 4 weeks, and do not expect clinical effects from dose adjustments earlier than 3 weeks post-injection. 1 This reflects the pharmacokinetic profile where steady-state is not achieved immediately.
Administration Specifics
- Administer deep IM into deltoid (using 1-inch needle, alternating arms) or gluteal muscle (using 2-inch needle, alternating buttocks) 1
- Must be administered by healthcare professional 1
- Never administer intravenously - avoid inadvertent vascular administration 1
Clinical Context for LAI Use
Guidelines strongly support LAI formulations for patients with: 3, 4
- History of non-adherence leading to relapse 3
- Recurrent relapses related to partial or full non-adherence 3
- Patient preference for convenience 3
- Need to avoid covert non-adherence 3
The 2025 INTEGRATE guidelines emphasize that LAI availability should be considered early in treatment planning, particularly when adherence is a clinical priority. 4
Common Pitfalls to Avoid
Do not skip the 3-week oral overlap - this is the most critical error that leads to symptom breakthrough. Studies switching patients directly from oral antipsychotics to LAI without oral risperidone overlap were successful, but only because they maintained the previous oral antipsychotic during the initial 3 weeks. 5
Do not use the outdated conversion ratio - older FDA labeling suggested ≤4 mg oral → 25 mg LAI, but pharmacokinetic data demonstrates this underdoses many patients. 2 The refined conversion (≤3 mg → 25 mg LAI) better maintains therapeutic levels.
Do not expect immediate dose adjustments to show effect - wait the full 4 weeks between adjustments and 3 weeks to assess response. 1